Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient

Trial Profile

Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top